Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret A Tempero et al. J Natl Compr Canc Netw. 2017 Aug.

Abstract

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

PubMed Disclaimer

Similar articles

  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks. Tempero MA, et al. J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13. doi: 10.6004/jnccn.2012.0073. J Natl Compr Canc Netw. 2012. PMID: 22679115 Free PMC article.
  • Pancreatic Adenocarcinoma, Version 1.2019.
    Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Tempero MA, et al. J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014. J Natl Compr Canc Netw. 2019. PMID: 30865919
  • Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Tempero MA, et al. J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017. J Natl Compr Canc Netw. 2021. PMID: 33845462
  • Defining and Treating Borderline Resectable Pancreatic Cancer.
    Perri G, Prakash L, Katz MHG. Perri G, et al. Curr Treat Options Oncol. 2020 Jul 28;21(9):71. doi: 10.1007/s11864-020-00769-1. Curr Treat Options Oncol. 2020. PMID: 32725270 Review.
  • Management of Locally Advanced Pancreatic Cancer.
    Martin RC 2nd. Martin RC 2nd. Surg Clin North Am. 2016 Dec;96(6):1371-1389. doi: 10.1016/j.suc.2016.07.010. Surg Clin North Am. 2016. PMID: 27865283 Review.
See all similar articles

Cited by

See all "Cited by" articles

Publication types